Clinical effectiveness of medical ozone therapy in COVID-19: the evidence and gaps map
Serra MEG, Baeza-Noci J, Abdala CVM, et al. Medical Gas Research, 2023.
- Study type
- Narrative review
- People studied
- 271 people, across the studies it reviews
- Population
- Patients across 13 pooled clinical studies of medical ozone therapy in COVID-19
- Published
- 2023, Medical Gas Research
- Identifiers
- PMID 37077114, DOI 10.4103/2045-9912.372819
What the authors reported
An evidence-and-gaps map of 13 clinical studies (271 patients total) on medical ozone therapy for COVID-19, mostly major or minor autohemotherapy or rectal insufflation in acute, often hospitalized infection.
What limits this result
Authored by ozone-therapy society members; maps existing acute-COVID studies rather than long COVID, and includes no EBO2-specific study.
Other ozone methods, such as major autohemotherapy, that clinics cite in support of EBO2. A result for one method does not transfer automatically to another. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.
Where we cite this study
EBO2 (EBOO) for Long COVID: What Has Been Studied
What NIH RECOVER, FDA enforcement action, and small ozone autohemotherapy trials actually show about EBO2 (also called EBOO) and long COVID symptoms.